Clinical Trials Sponsored by Janssen Diagnostics, LLC

Total 1331 results

Janssen Research & Development, LLC

Completed

A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Under Fed Conditions

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus

Respiratory Syncytial Virus Infections

United States, Taiwan, Japan, Korea, Republic of, France, Mexico, Brazil, Sweden, Argentina, Ukraine, Canada, Spain, Germany, Poland, Belgium, Russian Federation, South Africa, Australia, Bulgaria
Janssen Research & Development, LLC

Completed

A Study of Lazertinib (JNJ-73841937) in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease

Respiratory Syncytial Viruses

Taiwan, Belgium, United Kingdom, Argentina, Panama
Janssen Research & Development, LLC

Completed

AAVCAGsCD59 for the Treatment of Wet AMD

Wet Age-related Macular Degeneration

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive Disorder

Depressive Disorder, Major

Germany, Netherlands
Janssen Research & Development, LLC

Completed

A Study of 14C JNJ-67953964 in Healthy Adult Male Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study of Bermekimab in Patients With Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal Function

Kidney Failure, Chronic

United States
Janssen Research & Development, LLC

Completed

A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostatic Neoplasms

Canada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
Janssen Research & Development, LLC

Completed

A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants

Healthy

United States, Germany
Janssen Research & Development, LLC

Completed

A Study Exploring the Use of Challenge Agents in Healthy Volunteers or Participants With a Disease of Interest

Healthy

Belgium
Janssen Scientific Affairs, LLC

Completed

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (DREaM)

Psychotic Disorders | Schizophrenia

United States, Brazil, Mexico
Janssen Research & Development, LLC

Completed

A Study of JNJ-77474462 (Bermekimab) in Healthy Participants of Japanese Descent Following Administration of Single Ascending Subcutaneous Doses

Healthy

Australia
Janssen Research & Development, LLC

Completed

A Study of Sublingually Administered (S)-Ketamine Oral Solution in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes

Pre-Symptomatic Type 1 Diabetes

United States, Finland, Sweden
Janssen Research & Development, LLC

Completed

A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder

Phobic Disorders

United States, Australia, Canada
Janssen Research & Development, LLC

Completed

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment (VOYAGE 2)

Psoriasis

United States, Australia, Poland, Germany, Spain, Korea, Republic of, Canada, Russian Federation, Czechia
Janssen Research & Development, LLC

Terminated

A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer (XCITE)

Metastatic Colorectal Cancer

United States, Spain, Australia, Belgium, Israel, Austria, Czechia, United Kingdom, Hungary, Italy, Netherlands, Poland, Switzerland
Janssen Research & Development, LLC

Approved for marketing

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

Metastatic Non-Small Cell Lung Cancer
Janssen Research & Development, LLC

Completed

A Study Exploring the Use of Challenge Agents in Healthy Volunteers - Intervention Specific Appendix

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of (14C)-JNJ-73841937 (Lazertinib) in Healthy Male Participants

Healthy

Netherlands
Janssen Research & Development, LLC

No longer available

Pre-approval Access for Janssen's COVID Vaccine VAC31518 for Treating Physician Use

Healthy
Janssen Research & Development, LLC

Completed

A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer

Advanced Colorectal Cancer | Symptomatic Colorectal Cancer | Colorectal Cancer With Cachexia

Poland
Janssen Research & Development, LLC

Completed

Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis.

Patients Undergoing Repeat Peripheral Artery Revascularization

United States
Janssen Research & Development, LLC

Completed

Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis

Psoriasis

United States
Janssen Research & Development, LLC

Completed

Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants

Healthy

China
Janssen Research & Development, LLC

Completed

A Study to Assess the Effects of Acid-Reducing Agent(s) on JNJ-64417184 in Healthy Participants

Healthy Participants

Netherlands
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Crohn's Disease | Colitis | Inflammatory Bowel Disease | IBD

United States, France, Poland, United Kingdom, Germany, Spain, Israel, Bulgaria, Serbia, South Africa, Japan, Canada, Australia, Netherlands, Korea, Republic of, Belgium, New Zealand, Brazil, Russian Federation, Austria, Hungary, ... and more
Janssen Research & Development, LLC

Completed

A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)

Prostatic Neoplasms

United States, Canada
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy (PRELUDE)

Macular Degeneration | Geographic Atrophy | Visual Acuity

United States
Janssen Research & Development, LLC

Completed

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression (SUSTAIN-2)

Treatment-resistant Depression

United States, Australia, France, United Kingdom, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Poland, Bulgaria, Malaysia, South Africa, Turkey, Finland, Korea, Republic of, Brazil, Austria, Sweden, Lithuania
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (TRANSFORM-1)

Treatment-resistant Depression

United States, France, Belgium, Mexico, Canada, Brazil, Estonia, Hungary, Slovakia
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection

Influenza A Virus

United States, France, Belgium, Germany, Hong Kong, Spain, Malaysia, Turkey, Canada, Netherlands, Singapore, Brazil, New Zealand, Australia, Sweden
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-53718678 Administered as Oral Concept Formulation Compared to the Current Oral Solution and to Assess the Effect of Food on the Pharmacokinetics of Oral Concept Formulation

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)

Healthy

United States
Janssen Research & Development, LLC

Completed

Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma

Carcinoma, Hepatocellular

China, Taiwan, Korea, Republic of
Janssen Research & Development, LLC

Completed

A Study of New Transdermal Contraceptive Patch at End of Shelf Life and Currently Marketed EVRA at the Beginning of Shelf Life in Healthy Women

Healthy

Netherlands, Germany, Belgium
Janssen Research & Development, LLC

Approved for marketing

Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)

Depressive Disorder, Treatment-Resistant
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

Obesity

United States, Belgium, United Kingdom, Sweden, Poland, Canada
Janssen Research & Development, LLC

Completed

A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study in Healthy Volunteers to Assess the Effect of Different Types of Food on a Single-dose of JNJ-64417184 Administered as Tablets

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan

Attention Deficit Disorder With Hyperactivity

United States
Janssen Research & Development, LLC

Terminated

An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung

Adenocarcinoma of Lung

Spain, Belgium, United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery (TEXT-TKR)

VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery

Belgium, Italy, Malaysia, Latvia, Spain, Turkey, Bulgaria, United States, Lithuania, Russian Federation, Ukraine, Japan, Argentina, Brazil, Canada, Poland
Janssen Research & Development, LLC

Completed

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

Attention Deficit Disorder With Hyperactivity

United States
Janssen Research & Development, LLC

Completed

Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)

Alzheimer Disease

France, Belgium, Germany, Spain, Sweden

3

Subscribe